Q3 FY2023 · ended Sep 30, 2023 · Revenue $1,520, -86.1% YoY · Filed Dec 29, 2023
Endonovo Therapeutics, Inc. (ENDV) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. In Q3 of fiscal 2023, the quarter ended Sep 30, 2023, it reported revenue of $1,520 and a net loss of $766,170. As of Sep 30, 2023 it held $0 in cash and investments and $7.1 million in total debt.
Revenue
$1,520
-86.1% vs year-ago quarter
Net income
$-766,170
-27.0% vs year-ago quarter
Operating cash flow
$-65,367
+47.2% vs year-ago quarter
Free cash flow
—
EPS
$0.00
+100.0% vs prior quarter
Dividend per share
None
Shares outstanding
318.75M
+64.0% vs year-ago quarter
Net cash
$-7.09M
Q3 FY2023
Operating margin
-1023.2%
TTM
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- ENDV (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Woodland Hills, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1528172
- Former names
- Hanover Portfolio Acquisitions, Inc. (until Jan 24, 2014)
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2023 Sep 30, 2023 |
Q2 FY2023 Jun 30, 2023 |
Q1 FY2023 Mar 31, 2023 |
Q4 FY2022 Dec 31, 2022 |
Q3 FY2022 Sep 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $1,520 | $45,200 | $87,540 | $121,463 | $10,960 |
| Operating income | -$472,797 | -$1.1M | -$529,290 | -$483,051 | -$496,778 |
| Net income | -$766,170 | $2.1M | $7.2M | -$12.9M | -$603,360 |
| Diluted EPS | $0.00 | -$0.01 | $0.00 | — | — |
| Operating cash flow | -$65,367 | -$165,840 | -$173,156 | -$225,541 | -$123,861 |
| Total assets | $815,764 | $1.0M | $1.2M | $1.3M | $1.5M |
| Total liabilities | $23.8M | $23.2M | $25.6M | $33.5M | $21.1M |
| Stockholders' equity | -$23.0M | -$22.4M | -$24.4M | -$32.2M | -$19.6M |
| Cash and investments | $0 | $32,602 | $10,942 | — | $23,139 |
| Total debt | $7.1M | $7.1M | $6.9M | $7.2M | $7.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Jan 3, 2024 | Dec 29, 2023 |
| 10-Q/A | Amended quarterly report | Dec 29, 2023 | Sep 30, 2023 |
| 10-Q | Quarterly report | Dec 29, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Material agreement
|
Dec 4, 2023 | Dec 4, 2023 |
| 8-K |
Current report
Other events
|
Oct 12, 2023 | Oct 5, 2023 |
| 10-Q | Quarterly report | Aug 21, 2023 | Jun 30, 2023 |
All 502 Endonovo Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.